A R Davies1,2,3, D Myoteri4, J Zylstra1,2,3, C R Baker1,2, W Wulaningsih5, M Van Hemelrijck5, N Maisey6, W H Allum7, E Smyth7, J A Gossage1,2,3, J Lagergren1,2,3, D Cunningham7,8, M Green4. 1. Department of Surgery, Guy's and St Thomas' Oesophago-Gastric Centre, London, UK. 2. Gastrointestinal Cancer, King's College London, London, UK. 3. Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. 4. Department of Cellular Pathology, Guy's and St Thomas' Oesophago-Gastric Centre, London, UK. 5. Translational Oncology and Urology Research, School of Cancer Sciences, King's College London, London, UK. 6. Department of Oncology, Guy's Cancer Centre, Guy's Hospital, London, UK. 7. Department of Oncology, Royal Marsden Hospital, London, UK. 8. Institute of Cancer Research, London, UK.
Abstract
BACKGROUND: The aim was to define the pathological response in lymph nodes following neoadjuvant chemotherapy for oesophageal adenocarcinoma and to quantify any associated survival benefit. METHODS: Lymph nodes retrieved at oesophagectomy were examined retrospectively by two pathologists for evidence of a response to chemotherapy. Patients were classified as lymph node-negative (either negative nodes with no evidence of previous tumour involvement or negative with evidence of complete regression) or positive (allocated a lymph node regression score based on the proportion of fibrosis to residual tumour). Lymph node responders (score 1, complete response; 2, less than 10 per cent remaining tumour; 3, 10-50 per cent remaining tumour) and non-responders (score 4, more than 50 per cent viable tumour; 5, no response) were compared in survival analyses using Kaplan-Meier and Cox regression analysis. RESULTS: Among 377 patients, 256 had neoadjuvant chemotherapy. Overall, 68 of 256 patients (26·6 per cent) had a lymph node response and 115 (44·9 per cent) did not. The remaining 73 patients (28·5 per cent) had negative lymph nodes with no evidence of regression. Some patients had a lymph node response in the absence of a response in the primary tumour (27 of 99, 27 per cent). Lymph node responders had a significant survival benefit (P < 0·001), even when stratified by patients with or without a response in the primary tumour. On multivariable analysis, lymph node responders had decreased overall (hazard ratio 0·53, 95 per cent c.i. 0·36 to 0·78) and disease-specific (HR 0·42, 0·27 to 0·66) mortality, and experienced reduced local and systemic recurrence. CONCLUSION: Lymph node regression is a strong prognostic factor and may be more important than response in the primary tumour.
BACKGROUND: The aim was to define the pathological response in lymph nodes following neoadjuvant chemotherapy for oesophageal adenocarcinoma and to quantify any associated survival benefit. METHODS: Lymph nodes retrieved at oesophagectomy were examined retrospectively by two pathologists for evidence of a response to chemotherapy. Patients were classified as lymph node-negative (either negative nodes with no evidence of previous tumour involvement or negative with evidence of complete regression) or positive (allocated a lymph node regression score based on the proportion of fibrosis to residual tumour). Lymph node responders (score 1, complete response; 2, less than 10 per cent remaining tumour; 3, 10-50 per cent remaining tumour) and non-responders (score 4, more than 50 per cent viable tumour; 5, no response) were compared in survival analyses using Kaplan-Meier and Cox regression analysis. RESULTS: Among 377 patients, 256 had neoadjuvant chemotherapy. Overall, 68 of 256 patients (26·6 per cent) had a lymph node response and 115 (44·9 per cent) did not. The remaining 73 patients (28·5 per cent) had negative lymph nodes with no evidence of regression. Some patients had a lymph node response in the absence of a response in the primary tumour (27 of 99, 27 per cent). Lymph node responders had a significant survival benefit (P < 0·001), even when stratified by patients with or without a response in the primary tumour. On multivariable analysis, lymph node responders had decreased overall (hazard ratio 0·53, 95 per cent c.i. 0·36 to 0·78) and disease-specific (HR 0·42, 0·27 to 0·66) mortality, and experienced reduced local and systemic recurrence. CONCLUSION: Lymph node regression is a strong prognostic factor and may be more important than response in the primary tumour.
Authors: S A Rahman; R C Walker; M A Lloyd; B L Grace; G I van Boxel; B F Kingma; J P Ruurda; R van Hillegersberg; S Harris; S Parsons; S Mercer; E A Griffiths; J R O'Neill; R Turkington; R C Fitzgerald; T J Underwood Journal: Br J Surg Date: 2020-01-30 Impact factor: 6.939
Authors: John M Findlay; Edward Dickson; Cristina Fiorani; Kevin M Bradley; Somnath Mukherjee; Richard S Gillies; Nicholas D Maynard; Mark R Middleton Journal: Eur Radiol Date: 2019-07-05 Impact factor: 5.315
Authors: Karol Rawicz-Pruszyński; Bogumiła Ciseł; Radosław Mlak; Jerzy Mielko; Magdalena Skórzewska; Magdalena Kwietniewska; Agnieszka Pikuła; Katarzyna Gęca; Katarzyna Sędłak; Andrzej Kurylcio; Wojciech P Polkowski Journal: Cancers (Basel) Date: 2019-12-01 Impact factor: 6.639
Authors: S K Kamarajah; M Navidi; S Wahed; A Immanuel; N Hayes; S M Griffin; A W Phillips Journal: Ann Surg Oncol Date: 2020-03-21 Impact factor: 5.344
Authors: Willem J Koemans; Ruben T H M Larue; Maximilian Kloft; Jessica E Ruisch; Inge Compter; Robert G Riedl; Lara R Heij; Wouter van Elmpt; Maaike Berbée; Jeroen Buijsen; Philippe Lambin; Meindert N Sosef; Heike I Grabsch Journal: Esophagus Date: 2020-09-05 Impact factor: 4.230
Authors: Eliza Hagens; Karina Tukanova; Sara Jamel; Mark van Berge Henegouwen; George B Hanna; Suzanne Gisbertz; Sheraz R Markar Journal: Dis Esophagus Date: 2022-01-07 Impact factor: 3.429